PDSB net incomeQ2 2026-$9.75M
PDSB net income was -$9.75M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$9.43M a year earlier. For the full fiscal 2025 it was -$34.50M, compared with -$37.61M in fiscal 2024.
PDS Biotechnology Corporation (PDSB) financials
For the twelve months ended Jun 30, 2026, PDS Biotechnology Corporation reported -$33.67M of net income.
- Net income, TTM
- -$33.67M
- EPS, diluted, TTM
- -$0.63
- Cash
- $5.60M
- Market cap
- $113.4M
FY2016FY2025
FY2016FY2025
PDSB revenue and earnings growth
PDSB EPSQ2 2026-$0.18
PDSB diluted EPS was -$0.18 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.21 a year earlier. For the full fiscal 2025 it was -$0.74, compared with -$1.03 in fiscal 2024.
PDSB free cash flowQ4 2025-$3.70M
PDSB free cash flow was -$3.70M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$8.23M a year earlier. For the full fiscal 2025 it was -$27.75M, compared with -$35.06M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $19.03M | $22.57M | $27.76M | $29.43M | $11.25M | $7.92M | $6.10M | $830.7K | $34.31M | $24.83M |
| Selling, general and admin | $12.52M | $13.76M | $15.28M | $12.24M | $10.18M | $6.98M | $10.98M | $2.79M | $17.65M | $14.69M |
| Operating income | -$31.54M | -$36.32M | -$43.05M | -$41.67M | -$21.44M | -$14.90M | -$21.03M | -$3.65M | -$51.97M | -$39.51M |
| Interest expense | $5.34M | $4.67M | $4.21M | $1.32M | $0 | $0 | $33.6K | $3.6K | $2.18M | $1.20M |
| Pre-tax income | -$35.67M | -$38.48M | -$44.35M | -$42.05M | -$21.43M | -$14.85M | -$7.38M | -$3.84M | -$53.45M | -$40.67M |
| Income tax | -$1.17M | -$869.2K | -$1.41M | -$1.20M | -$4.52M | $0 | -$381.5K | $0 | -$2.59M | -$1.85M |
| Net income | -$34.50M | -$37.61M | -$42.94M | -$40.85M | -$16.92M | -$14.85M | -$7.00M | -$3.84M | -$50.86M | -$38.82M |
| EPS, basic | -$0.74 | -$1.03 | -$1.39 | -$1.43 | -$0.66 | -$0.89 | -$1.44 | $1.15 | - | - |
| EPS, diluted | -$0.74 | -$1.03 | -$1.39 | -$1.43 | -$0.66 | -$0.89 | -$1.44 | $1.15 | - | - |
| Diluted shares | 46.4M | 36.5M | 31.0M | 28.6M | 25.6M | 16.7M | 4.9M | 3.3M | 30.4M | 28.9M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $26.71M | $41.69M | $56.56M | $73.82M | $65.24M | $28.84M | $12.16M | $103.7K | $175.9K | $106.40M |
| Current assets | $28.25M | $45.05M | $59.06M | $76.48M | $66.84M | $30.34M | $14.47M | $122.1K | $89.05M | $107.35M |
| Total assets | $30.49M | $45.36M | $59.39M | $77.01M | $67.20M | $30.89M | $14.49M | $164.4K | $92.62M | $110.91M |
| Current liabilities | $9.48M | $17.09M | $13.63M | $9.82M | $3.76M | $3.27M | $2.79M | $1.91M | $12.87M | $6.68M |
| Long-term debt | - | - | - | - | - | - | $0 | $30.0K | - | - |
| Total debt | - | - | - | - | - | - | $0 | $30.0K | - | - |
| Total liabilities | $21.24M | $26.35M | $33.26M | $33.01M | $3.99M | $3.76M | $2.79M | $2.23M | - | - |
| Shareholders' equity | $9.25M | $19.00M | $26.13M | $44.00M | $63.21M | $27.13M | $11.70M | -$2.07M | -$609.5K | $89.28M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.75M | -$35.03M | -$33.64M | -$25.71M | -$12.49M | -$13.15M | -$18.07M | -$1.57M | -$40.70M | -$32.19M |
| Capital expenditures | $0 | $29.0K | $0 | - | - | - | - | $0 | $188.7K | $686.7K |
| Free cash flow | -$27.75M | -$35.06M | -$33.64M | - | - | - | - | -$1.57M | -$40.89M | -$32.88M |
| Investing cash flow | $0 | -$29.0K | $0 | - | - | $0 | $29.38M | $0 | -$188.7K | -$686.7K |
| Financing cash flow | $12.77M | $20.19M | $16.38M | $34.29M | $48.89M | $29.83M | $750.0K | $1.50M | $22.55M | $9.08M |
| Stock-based compensation | $4.11M | $6.85M | $7.61M | $5.20M | $4.07M | $432.3K | $3.14M | $866.8K | $6.18M | $5.31M |
| Depreciation and amortization | - | - | - | - | - | $15.6K | $0 | $69.1K | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -372.9% | -197.9% | -164.3% | -92.8% | -26.8% | -54.7% | -59.8% | - | - | -43.5% |
| Return on assets | -113.1% | -82.9% | -72.3% | -53.1% | -25.2% | -48.1% | -48.3% | -2333.2% | -54.9% | -35.0% |
| Current ratio | 2.98 | 2.64 | 4.33 | 7.79 | 17.80 | 9.28 | 5.18 | 0.06 | 6.92 | 16.06 |
| Debt to equity | - | - | - | - | - | - | 0.00 | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.27M | $3.46M | $4.41M | $4.58M | $4.21M | $5.83M | $4.53M | $6.80M | $4.53M | $6.70M | $7.47M | $6.45M |
| Selling, general and admin | $3.23M | $3.06M | $2.27M | $3.56M | $3.41M | $3.27M | $2.83M | $3.37M | $4.16M | $3.39M | $2.94M | $4.07M |
| Operating income | -$6.50M | -$6.52M | -$6.67M | -$8.14M | -$7.62M | -$9.11M | -$7.36M | -$10.18M | -$8.68M | -$10.10M | -$10.41M | -$10.52M |
| Interest expense | $3.38M | $1.01M | $1.11M | $1.15M | $2.14M | $930.9K | $1.10M | $1.21M | $1.19M | $1.17M | $1.17M | $1.07M |
| Pre-tax income | -$9.75M | -$7.35M | -$7.56M | -$9.01M | -$9.43M | -$9.66M | -$7.95M | -$10.73M | -$9.20M | -$10.60M | -$10.90M | -$10.85M |
| Income tax | $0 | $0 | $0 | $0 | $0 | -$1.17M | $0 | $0 | -$869.2K | $0 | $2 | $0 |
| Net income | -$9.75M | -$7.35M | -$7.56M | -$9.01M | -$9.43M | -$8.49M | -$7.95M | -$10.73M | -$8.33M | -$10.60M | -$10.90M | -$10.85M |
| EPS, basic | -$0.18 | -$0.13 | -$0.13 | -$0.19 | -$0.21 | -$0.21 | -$0.21 | -$0.29 | -$0.23 | -$0.30 | -$0.35 | -$0.35 |
| EPS, diluted | -$0.18 | -$0.13 | -$0.13 | -$0.19 | -$0.21 | -$0.21 | -$0.21 | -$0.29 | -$0.23 | -$0.30 | -$0.35 | -$0.35 |
| Diluted shares | 55.7M | 55.5M | - | 46.9M | 45.9M | 40.5M | - | 36.8M | 36.7M | 34.8M | - | 30.9M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.60M | $21.66M | $26.71M | $26.20M | $31.87M | $39.98M | $41.69M | $49.75M | $57.73M | $66.63M | $56.56M | $54.25M |
| Current assets | $7.05M | $22.89M | $28.25M | $27.89M | $33.65M | $42.47M | $45.05M | $52.13M | $60.16M | $68.69M | $59.06M | $56.84M |
| Total assets | $8.81M | $24.66M | $30.49M | $34.71M | $40.48M | $47.03M | $45.36M | $52.45M | $60.50M | $69.01M | $59.39M | $57.19M |
| Current liabilities | $12.38M | $10.15M | $9.48M | $13.33M | $11.53M | $18.27M | $17.09M | $18.34M | $15.67M | $15.06M | $13.63M | $9.15M |
| Total liabilities | $12.39M | $20.77M | $21.24M | $25.25M | $24.52M | $24.67M | $26.35M | $30.45M | $29.58M | $31.82M | $33.26M | $32.70M |
| Shareholders' equity | -$3.58M | $3.89M | $9.25M | $9.45M | $15.96M | $22.36M | $19.00M | $22.00M | $30.92M | $37.18M | $26.13M | $24.48M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.79M | -$4.37M | -$3.70M | -$5.92M | -$9.10M | -$9.03M | -$8.23M | -$8.00M | -$8.86M | -$9.94M | -$8.46M | -$7.18M |
| Capital expenditures | - | - | $0 | $0 | - | - | $0 | $1 | - | - | $0 | $0 |
| Free cash flow | - | - | -$3.70M | -$5.92M | - | - | -$8.23M | -$8.00M | - | - | -$8.46M | -$7.18M |
| Investing cash flow | - | - | $0 | $0 | - | - | $0 | -$1 | - | - | $0 | $0 |
| Financing cash flow | -$13.27M | -$679.8K | $4.22M | $241.2K | $995.9K | $7.32M | $172.8K | $17.2K | -$13.8K | $20.01M | $10.77M | $802.3K |
| Stock-based compensation | $1.13M | $1.16M | $1.16M | $1.25M | $448.0K | $1.25M | $1.64M | $1.78M | $1.80M | $1.63M | $1.35M | $2.07M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.57 | 2.26 | 2.98 | 2.09 | 2.92 | 2.33 | 2.64 | 2.84 | 3.84 | 4.56 | 4.33 | 6.21 |
Source: XBRL data PDS Biotechnology Corporation files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PDSB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PDSB | - | - | -$33.67M | - | $113.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
PDSB FAQ
5 questionsIs PDSB profitable?
No. PDS Biotechnology Corporation reported a net loss of $33.67M for the twelve months ended Jun 30, 2026.How much cash and debt does PDSB have?
PDS Biotechnology Corporation reported $5.60M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is PDSB earnings per share?
Diluted earnings per share were -$0.63 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did PDSB last report financial results?
The latest statements here come from PDS Biotechnology Corporation's 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this PDSB financial data come from?
Quantisnow builds these statements from the structured XBRL data PDS Biotechnology Corporation files with the SEC. It is provided for information only and is not investment advice.